56.27
25.25 (00.45%)
As of Mar 06, 2024
EXACT SCIENCES CORP [EXAS]
As of Feb 21, 2024 | Source: Annual Report to the SEC
Company Overview
Exact Sciences Corporation is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer screening and diagnostics, and are currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
| Country | United States |
| Headquarters | Madison, Wisconsin |
| Phone Number | 608-284-5700 |
| Industry | Health Services |
| Employees | 6,600 |
| CEO | Kevin T. Conroy |
| Website | www.exactsciences.com |
Key fundamental financials loss of $74.15 million Revenue of $602.45 million Current Reporting Revenue Net Income Profit/Loss Mar 2023 $602.45 million $74.15 million loss Sep 2022 $0.5231 million $0.1...
Key fundamental financials loss of $74.15 million Revenue of $602.45 million Exact Sciences Corp [EXAS] has reported $74.15 million loss for the fiscal quarter ending Mar 31, 2023. Revenue for the qua...
Net Sales: $2,084.28M EXACT SCIENCES CORP [EXAS] posted a loss of $623.51M, marking a fall of 4.68% for this year. Revenue rose to $2,084.28M this year compared to $1,767.09M in the previous year. Acc...
EXACT SCIENCES CORP [EXAS] As of Nov 03, 2022| Source: Quarterly Report to the SEC Exact Sciences Corporation (together with its subsidiaries, Exact, we, us, our or the Company) is a leading, global, ...
EXACT SCIENCES CORP [EXAS] As of Aug 02, 2022| Source: Quarterly Report to the SEC Exact Sciences Corporation (together with its subsidiaries, Exact, we, us, our or the Company) is a leading, global, ...
Financial Overview
| Revenue | 2,499,766 K |
| Operating Revenue | -215,012 K |
| Profits | -204,149 K |
| Net Cash | 366,885 K |
Management Effectiveness
| Return on Equity | -6.49% |
| Return on Assets | -3.15% |
| Turnover Ratio | 0.39 K |
| EBITDA | -122,852 K |
Profit Ratios
| Gross Margin | 1,845,518 K |
| Operating Margin | -8.6% |
| Profit as % of Revenues | -904.01% |
| Profit as % of Assets | -3.22% |
| Profit as % of Stockholder Equity | -6.49% |
Balance Sheet and Cash Flow Measures
| Total Assets | 6,471,334 K |
| Total Liabilities | 3,326,029 K |
| Operating Cash Flow | 156,119 K |
| Investing Cash Flow | 49,679 K |
| Financing Cash Flow | 159,766 K |